Penn Medicine Provider
About me
- Vice Chief and Director, Lung Research, Pulmonary and Critical Care Medicine
- Professor of Medicine (Pulmonary, Allergy and Critical Care)
My education and training
- University of Pennsylvania Health SystemResidency
- University of Pennsylvania Health SystemFellowship
Spoken languages
English
English
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Albelda is a Penn Medicine physician.
Qualifications and experience
- Pulmonary Disease, 1984
- American Society for Clinical Investigation, National
- Sigma Xi, Research Society of North America, Associate Member, National
Treatments and conditions
Research
Publications
Bengsch Bertram, Ohtani Takuya, Khan Omar, Setty Manu, Manne Sasikanth, O'Brien Shaun, Gherardini Pier Federico, Herati Ramin Sedaghat, Huang Alexander C, Chang Kyong-Mi, Newell Evan W, Bovenschen Niels, Pe'er Dana, Albelda Steven M, Wherry E John Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. , Immunity, 48(5): 2018,1029-1045.e5
Aggarwal Charu, Haas Andrew R, Metzger Susan, Aguilar Laura K, Aguilar-Cordova Estuardo, Manzanera Andrea G, Gómez-Hernández Gregoria, Katz Sharyn I, Alley Evan W, Evans Tracey L, Bauml Joshua M, Cohen Roger B, Langer Corey J, Albelda Steven M, Sterman Daniel H Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. , Molecular therapy : the journal of the American Society of Gene Therapy, 26(5): 2018,1198-1205
Scherpereel Arnaud, Wallyn Frederic, Albelda Steven M, Munck Camille Novel therapies for malignant pleural mesothelioma. , The Lancet. Oncology, 19(3): 2018,e161-e172
Negorev Dmitri, Beier Ulf H, Zhang Tianyi, Quatromoni Jon G, Bhojnagarwala Pratik, Albelda Steven M, Singhal Sunil, Eruslanov Evgeniy, Lohoff Falk W, Levine Matthew H, Diamond Joshua M, Christie Jason D, Hancock Wayne W, Akimova Tatiana Human neutrophils can mimic myeloid-derived suppressor cells (PMN-MDSC) and suppress microbead or lectin-induced T cell proliferation through artefactual mechanisms. , Scientific reports, 8(1): 2018,3135
Moon Edmund K, Wang Liang-Chuan S, Bekdache Kheng, Lynn Rachel C, Lo Albert, Thorne Stephen H, Albelda Steven M Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. , Oncoimmunology, 7(3): 2018,e1395997
Aggarwal Charu, Wang Xingmei, Ranganathan Anjana, Torigian Drew, Troxel Andrea, Evans Tracey, Cohen Roger B, Vaidya Bhavesh, Rao Chandra, Connelly Mark, Vachani Anil, Langer Corey, Albelda Steven Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy. , Lung cancer (Amsterdam, Netherlands), 112: 2017,118-125
Pietrofesa RA, Woodruff P, Hwang WT, Patel P, Chatterjee S, Albelda SM, Christofidou-Solomidou M The synthetic lignan secoisolariciresinol diglucoside prevents asbestos-induced NLRP3 inflammasome activation in murine macrophages. , Oxidative medicine and cellular longevity, 2017: 2017,7395238
Wang Liang-Chuan S, Lo Albert, Scholler John, Sun Jing, Majumdar Rajrupa S, Kapoor Veena, Antzis Michael, Cotner Cody E, Johnson Laura A, Durham Amy C, Solomides Charalambos C, June Carl H, Puré Ellen, Albelda Steven M Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity. , Cancer immunology research, 2(2): 2014,154-66
Moon EK1, Wang LC2, Dolfi DV3, Wilson CB4, Ranganathan R2, Sun J2, Kapoor V2, Scholler J4, Puré E5, Milone MC4, June CH4, Riley JL3, Wherry EJ3, Albelda SM2. Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors. , Clinical Cancer Research, 20(16): 2014,1-12
Moon Edmund K, Ranganathan Raghuveer, Eruslanov Evgeniy, Kim Soyeon, Newick Kheng, O'Brien Shaun, Lo Albert, Liu Xiaojun, Zhao Yangbing, Albelda Steven M Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. , Clinical Cancer Research : an official journal of the American Association for Cancer Research, 22(2): 2016,436-47